Fotemustine

Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Fotemustine

Articles

Most recent articles on Fotemustine

Most cited articles on Fotemustine

Review articles on Fotemustine

Articles on Fotemustine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fotemustine

Images of Fotemustine

Photos of Fotemustine

Podcasts & MP3s on Fotemustine

Videos on Fotemustine

Evidence Based Medicine

Cochrane Collaboration on Fotemustine

Bandolier on Fotemustine

TRIP on Fotemustine

Clinical Trials

Ongoing Trials on Fotemustine at Clinical Trials.gov

Trial results on Fotemustine

Clinical Trials on Fotemustine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fotemustine

NICE Guidance on Fotemustine

NHS PRODIGY Guidance

FDA on Fotemustine

CDC on Fotemustine

Books

Books on Fotemustine

News

Fotemustine in the news

Be alerted to news on Fotemustine

News trends on Fotemustine

Commentary

Blogs on Fotemustine

Definitions

Definitions of Fotemustine

Patient Resources / Community

Patient resources on Fotemustine

Discussion groups on Fotemustine

Patient Handouts on Fotemustine

Directions to Hospitals Treating Fotemustine

Risk calculators and risk factors for Fotemustine

Healthcare Provider Resources

Symptoms of Fotemustine

Causes & Risk Factors for Fotemustine

Diagnostic studies for Fotemustine

Treatment of Fotemustine

Continuing Medical Education (CME)

CME Programs on Fotemustine

International

Fotemustine en Espanol

Fotemustine en Francais

Business

Fotemustine in the Marketplace

Patents on Fotemustine

Experimental / Informatics

List of terms related to Fotemustine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).

References


Linked-in.jpg